ArticleObstetrics & gynecology science2026
Promising survival prospects and immunotherapy potential in polymerase epsilon-mutated endometrial cancer: a comprehensive systematic review and meta-analysis unveiling future therapeutic opportunities.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Polymerase epsilon mutations in endometrial cancer: addressing heterogeneity, clinical applicability, and methodological refinements.Obstetrics & gynecology science · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMutations in the DNA polymerase epsilon (POLE) gene in endometrial cancer define a distinct molecular subgroup with therapeutic relevance. This study evaluates their prognostic significance to refine risk stratification and guide treatment planning, especially within immunotherapy-based approaches.
methodsThis systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and was registered in the PROSPERO database (CRD420251064413). Cohort studies from 2018-2025 were retrieved from major databases. Study quality was assessed using the quality in prognostic studies tool. Hazard ratios for overall survival, disease-specific survival, and progression-free survival were synthesized using Review Manager 5.4 (Cochrane Collaboration, London, United Kingdom), and R statistical software 4.4.2 (R Foundation for Statistical Computing, Vienna, Austria) with heterogeneity assessed using the I-squared statistic and publication bias examined through funnel plots, Egger's test, and the Trim-and-Fill method.
resultsPOLE mutations were identified in 9% of endometrial cancer cases (95% confidence interval, 9-11%; I2=90.6%; P<0.0001). Patients with POLE mutations showed significantly improved progression-free survival (hazard ratio, 0.37; 95% confidence interval, 0.26-0.53; I2=0%) and overall survival (hazard ratio, 0.57; 95% confidence interval, 0.40-0.79; I2=41%). Most cases were early stage (International Federation of Gynecology and Obstetrics I-II, 86%), endometrioid type (84%), with low myometrial invasion (<50%, 56%), limited lymphovascular space invasion (25%), and low lymph node metastasis (29%).
conclusionPOLE mutations in endometrial cancer are associated with a favorable prognosis and show promising potential for immunotherapy. Molecular subtyping that incorporates POLE mutation status should be considered standard practice for risk stratification and treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.